The experiments described in this paper were performed in order to elucidate a possible regulatory role of acute and chronic myeloid leukemic leucocytes. The influence of these cells on either activated or non-activated mouse bone marrow cells was measured, and the results were compared with the action of the two major leucocyte fractions, mononuclear cells and granulocytes. It was demonstrated that acute leukemic blasts were almost completely unable to activate myeloid committed stem cells (Colony Forming Units, CFUc). In contrast, blasts from patients with chronic myeloid leukemia (CML) in blastic crisis disclosed a variable pattern of activation, in that two out of three cases exerted normal stimulatory capacity. A possible inhibitory action of leukemic cells was the subject of further experiments. Acute leukemic blasts in some cases disclosed inhibitory activity, a few cases appeared to be without influence on normal proliferating CFUc. Granulocytes from patients with CML in the chronic phase showed inhibitory capacity when compared with granulocytes from normal individuals.

Keywords:
Colony forming unit, Colony stimulating factor, Colony inhibitory activity, Leukemic leucocytes
© 1977 S. Karger AG, Basel
1977
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.